Ignite Creation Date:
2024-07-17 @ 10:50 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06470282
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-06-17
Brief Title:
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Organization Data
Organization:
University of California San Francisco
Class:
OTHER
Study ID:
24522
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University of California San Francisco
Lead Sponsor Class:
OTHER
Responsible Party:
Vadim S Koshkin
Responsible Party Title:
Principal Investigator IND Holder
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
University of California San Francisco
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Astellas Pharma Inc | INDUSTRY |
| Merck Sharp Dohme LLC | INDUSTRY |